Sio Capital Management
Latest statistics and disclosures from Sio Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, LH, TFX, ZBH, SNN, and represent 53.02% of Sio Capital Management's stock portfolio.
- Added to shares of these 10 stocks: LH (+$50M), TFX (+$16M), SNN (+$14M), CRBP (+$10M), VXRT (+$9.9M), PCRX (+$9.8M), ABT (+$9.3M), KVUE (+$8.8M), ZBH (+$8.8M), IRON (+$8.7M).
- Started 14 new stock positions in SNN, BLCO, VSTM, ABT, CRBP, CNTX, CMPS, ZYME, LH, VXRT. BDSX, IRON, PMVP, KVUE.
- Reduced shares in these 10 stocks: , GMED (-$21M), CI (-$16M), MDGL (-$14M), , MDT (-$9.2M), EMBC (-$7.8M), HUMA (-$6.2M), HCSG (-$5.3M), Fusion Pharmaceuticals (-$5.2M).
- Sold out of its positions in CTMX, EMBC, Fusion Pharmaceuticals, GMED, HCSG, HUMA, IDYA, IART, IRWD, Laboratory Corp. of America Holdings. MDGL, OCUL, RVNC, SRRK, VINC, MDT.
- Sio Capital Management was a net buyer of stock by $1.8M.
- Sio Capital Management has $370M in assets under management (AUM), dropping by 10.03%.
- Central Index Key (CIK): 0001482416
Tip: Access up to 7 years of quarterly data
Positions held by Sio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sio Capital Management
Sio Capital Management holds 48 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 Put Option (INSM) | 24.7 | $91M | 1.4M | 67.00 |
|
|
| Labcorp Holdings Com Shs (LH) | 13.5 | $50M | NEW | 246k | 203.51 |
|
| Teleflex Incorporated (TFX) | 6.3 | $23M | +227% | 111k | 210.33 |
|
| Zimmer Holdings (ZBH) | 4.6 | $17M | +109% | 155k | 108.53 |
|
| Smith & Nephew Spdn Adr New (SNN) | 3.9 | $14M | NEW | 580k | 24.78 |
|
| Pacira Pharmaceuticals Put Option (PCRX) | 3.5 | $13M | +306% | 456k | 28.61 |
|
| Organon & Co Common Stock (OGN) | 3.4 | $13M | +26% | 608k | 20.70 |
|
| GSK Sponsored Adr (GSK) | 3.3 | $12M | +18% | 312k | 38.50 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.8 | $10M | NEW | 225k | 45.25 |
|
| Vaxart Com New (VXRT) | 2.7 | $9.9M | NEW | 15M | 0.67 |
|
| Tyra Biosciences (TYRA) | 2.6 | $9.6M | +12% | 600k | 15.99 |
|
| Abbott Laboratories (ABT) | 2.5 | $9.3M | NEW | 90k | 103.91 |
|
| Cigna Corp (CI) | 2.4 | $8.9M | -64% | 27k | 330.57 |
|
| Kenvue (KVUE) | 2.4 | $8.8M | NEW | 485k | 18.18 |
|
| Disc Medicine (IRON) | 2.3 | $8.7M | NEW | 192k | 45.07 |
|
| Erasca (ERAS) | 1.8 | $6.8M | +18% | 2.9M | 2.36 |
|
| Biodesix (BDSX) | 1.8 | $6.7M | NEW | 4.3M | 1.53 |
|
| Astria Therapeutics (ATXS) | 1.3 | $4.6M | +24% | 510k | 9.10 |
|
| Biosante Pharmaceuticals (ANIP) | 1.2 | $4.6M | -17% | 72k | 63.68 |
|
| Bausch Plus Lomb Corp Common Shares (BLCO) | 1.2 | $4.4M | NEW | 303k | 14.52 |
|
| Pmv Pharmaceuticals (PMVP) | 1.2 | $4.4M | NEW | 2.7M | 1.62 |
|
| Zymeworks Del (ZYME) | 1.1 | $4.2M | NEW | 491k | 8.51 |
|
| Bridgebio Pharma (BBIO) | 0.9 | $3.2M | -38% | 125k | 25.33 |
|
| Apogee Therapeutics (APGE) | 0.8 | $3.1M | 78k | 39.35 |
|
|
| Context Therapeutics (CNTX) | 0.7 | $2.7M | NEW | 1.3M | 2.00 |
|
| Modular Med Com New (MODD) | 0.7 | $2.4M | 1.5M | 1.58 |
|
|
| Stoke Therapeutics (STOK) | 0.6 | $2.4M | -22% | 175k | 13.51 |
|
| Enanta Pharmaceuticals (ENTA) | 0.6 | $2.3M | 177k | 12.97 |
|
|
| Third Harmonic Bio (THRD) | 0.6 | $2.1M | 163k | 13.00 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.5 | $2.0M | -50% | 668k | 2.92 |
|
| Silverback Therapeutics (SPRY) | 0.5 | $1.9M | -59% | 218k | 8.51 |
|
| Ventyx Biosciences (VTYX) | 0.5 | $1.8M | +106% | 779k | 2.31 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.5 | $1.8M | NEW | 293k | 6.04 |
|
| Arcutis Biotherapeutics (ARQT) | 0.4 | $1.5M | -74% | 160k | 9.30 |
|
| X4 Pharmaceuticals (XFOR) | 0.4 | $1.4M | -30% | 2.5M | 0.58 |
|
| Prelude Therapeutics (PRLD) | 0.3 | $1.2M | 320k | 3.81 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.3 | $1.1M | 277k | 4.07 |
|
|
| Rapt Therapeutics (RAPT) | 0.3 | $961k | 315k | 3.05 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $891k | +603% | 72k | 12.47 |
|
| Foghorn Therapeutics (FHTX) | 0.2 | $700k | 122k | 5.75 |
|
|
| Boundless Bio (BOLD) | 0.2 | $627k | +13% | 162k | 3.87 |
|
| Verastem Com New (VSTM) | 0.1 | $398k | NEW | 133k | 2.98 |
|
| Nyxoah S A SHS (NYXH) | 0.1 | $354k | 51k | 6.97 |
|
|
| Nextcure (NXTC) | 0.1 | $207k | 130k | 1.59 |
|
|
| Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $76k | 254k | 0.30 |
|
|
| Humacyte *w Exp 08/27/202 (HUMAW) | 0.0 | $71k | 50k | 1.41 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $29k | 400k | 0.07 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $199.804800 | 13k | 0.02 |
|
Past Filings by Sio Capital Management
SEC 13F filings are viewable for Sio Capital Management going back to 2010
- Sio Capital Management 2024 Q2 filed Aug. 14, 2024
- Sio Capital Management 2024 Q1 filed May 15, 2024
- Sio Capital Management 2023 Q3 filed Nov. 14, 2023
- Sio Capital Management 2023 Q2 filed Aug. 14, 2023
- Sio Capital Management 2023 Q1 filed May 12, 2023
- Sio Capital Management 2022 Q4 filed Feb. 13, 2023
- Sio Capital Management 2022 Q3 filed Nov. 14, 2022
- Sio Capital Management 2022 Q2 filed Aug. 15, 2022
- Sio Capital Management 2022 Q1 filed May 16, 2022
- Sio Capital Management 2021 Q4 filed Feb. 14, 2022
- Sio Capital Management 2021 Q3 filed Nov. 15, 2021
- Sio Capital Management 2021 Q2 filed Aug. 16, 2021
- Sio Capital Management 2021 Q1 filed May 14, 2021
- Sio Capital Management 2020 Q4 filed Feb. 16, 2021
- Sio Capital Management 2020 Q3 filed Nov. 16, 2020
- Sio Capital Management 2020 Q2 filed Aug. 14, 2020